Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUE NASDAQ:EPRX NASDAQ:RAPT NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/AEPRXEupraxia Pharmaceuticals$5.39+0.6%$5.38$2.20▼$6.20$192.74M1.4911,447 shs30,300 shsRAPTRapt Therapeutics$12.93+1.6%$10.61$5.67▼$26.56$210.53M-0.1110,672 shs91,956 shsVYGRVoyager Therapeutics$4.24+9.3%$3.37$2.64▼$8.27$215.22M0.9610,432 shs1.37 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUEbluebird bio0.00%0.00%0.00%0.00%-55.65%EPRXEupraxia Pharmaceuticals+0.56%+0.56%-0.55%+36.98%+120.00%RAPTRapt Therapeutics+1.57%+13.62%+29.43%+38.14%-20.77%VYGRVoyager Therapeutics+9.28%+26.19%+24.71%+19.77%-31.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/AEPRXEupraxia Pharmaceuticals$5.39+0.6%$5.38$2.20▼$6.20$192.74M1.4911,447 shs30,300 shsRAPTRapt Therapeutics$12.93+1.6%$10.61$5.67▼$26.56$210.53M-0.1110,672 shs91,956 shsVYGRVoyager Therapeutics$4.24+9.3%$3.37$2.64▼$8.27$215.22M0.9610,432 shs1.37 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUEbluebird bio0.00%0.00%0.00%0.00%-55.65%EPRXEupraxia Pharmaceuticals+0.56%+0.56%-0.55%+36.98%+120.00%RAPTRapt Therapeutics+1.57%+13.62%+29.43%+38.14%-20.77%VYGRVoyager Therapeutics+9.28%+26.19%+24.71%+19.77%-31.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUEbluebird bio 2.14Hold$25.75418.11% UpsideEPRXEupraxia Pharmaceuticals 3.17Buy$11.00104.08% UpsideRAPTRapt Therapeutics 2.50Moderate Buy$21.5766.83% UpsideVYGRVoyager Therapeutics 3.13Buy$13.25212.43% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, EPRX, RAPT, and VYGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025RAPTRapt TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/20/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/12/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$8.00 ➝ $9.008/8/2025RAPTRapt TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$51.00 ➝ $38.008/7/2025VYGRVoyager TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $8.007/30/2025RAPTRapt TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$14.007/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.007/22/2025RAPTRapt TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$31.007/10/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14EPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/ARAPTRapt Therapeutics$1.53M139.78N/AN/A$11.51 per share1.12VYGRVoyager Therapeutics$80M2.94N/AN/A$5.49 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/AEPRXEupraxia Pharmaceuticals-$25.50M-$0.85N/AN/AN/AN/A-367.73%-118.31%11/6/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$14.17N/AN/AN/AN/A-67.92%-59.59%11/11/2025 (Estimated)VYGRVoyager Therapeutics-$65M-$1.85N/AN/AN/A-253.49%-37.65%-28.89%11/11/2025 (Estimated)Latest BLUE, EPRX, RAPT, and VYGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EPRXEupraxia Pharmaceuticals-$0.21-$0.26-$0.05-$0.26N/AN/A8/7/2025Q2 2025RAPTRapt Therapeutics-$0.61-$0.65-$0.04-$0.65N/AN/A8/6/2025Q2 2025VYGRVoyager Therapeutics-$0.48-$0.57-$0.09-$0.57$9.50 million$5.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUEbluebird bioN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUEbluebird bio0.370.510.33EPRXEupraxia PharmaceuticalsN/A8.728.72RAPTRapt TherapeuticsN/A13.2513.25VYGRVoyager TherapeuticsN/A5.435.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUEbluebird bio87.43%EPRXEupraxia PharmaceuticalsN/ARAPTRapt Therapeutics99.09%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipBLUEbluebird bio1.40%EPRXEupraxia PharmaceuticalsN/ARAPTRapt Therapeutics2.36%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/ARAPTRapt Therapeutics8016.54 million16.15 millionOptionableVYGRVoyager Therapeutics10055.47 million51.93 millionOptionableBLUE, EPRX, RAPT, and VYGR HeadlinesRecent News About These CompaniesVoyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.25 Average Price Target from AnalystsAugust 27, 2025 | americanbankingnews.comVoyager to Present at Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from AnalystsAugust 26, 2025 | marketbeat.comVoyager Therapeutics Extends Cash Runway to 2028August 13, 2025 | msn.comTruist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)August 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from OppenheimerAugust 11, 2025 | theglobeandmail.comEquities Analysts Offer Predictions for VYGR Q3 EarningsAugust 11, 2025 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Estimates By $0.09 EPSAugust 10, 2025 | marketbeat.comVoyager Therapeutics (VYGR) Receives a Buy from Canaccord GenuityAugust 9, 2025 | theglobeandmail.comVoyager Therapeutics (NASDAQ:VYGR) Price Target Lowered to $8.00 at WedbushAugust 8, 2025 | marketbeat.comVoyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comVoyager Reports Second Quarter 2025 Financial and Operating ResultsAugust 6, 2025 | globenewswire.comVoyager 1 and 2: From Earth to Interstellar Space: The Final Frontier AwaitsJuly 21, 2025 | msn.comRead the NASA ‘Voyager Declaration’ Letter of DissentJuly 21, 2025 | nytimes.comMascarene Partners Acquires Voyager TruckingJuly 18, 2025 | finance.yahoo.comMascarene buys US waste services company Voyager TruckingJuly 18, 2025 | realassets.ipe.comRVoyager Therapeutics adds new gene therapy to Alzheimer’s programJuly 18, 2025 | bioworld.comBMascarene to acquire waste services transport firm Voyager Trucking CorporationJuly 18, 2025 | pehub.comLooking Beyond Voyager 1 And 2July 17, 2025 | msn.comRobert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of VoyagerJuly 16, 2025 | fandomwire.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLUE, EPRX, RAPT, and VYGR Company Descriptionsbluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Eupraxia Pharmaceuticals NASDAQ:EPRX$5.39 +0.03 (+0.56%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$5.37 -0.02 (-0.37%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Rapt Therapeutics NASDAQ:RAPT$12.93 +0.20 (+1.57%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.30 -0.63 (-4.87%) As of 09/5/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyVoyager Therapeutics NASDAQ:VYGR$4.24 +0.36 (+9.28%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$4.19 -0.05 (-1.16%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
